Toprol-XL is an extended-release tablet that belongs to a family of high blood pressure medications dubbed beta-blockers. It is indicated for control of hypertension, angina, and heart failure.
If approved, the investigational anti-PD-L1 IgG1 monoclonal antibody being developed by Merck and Pfizer could be Europe’s first treatment for metastatic MCC, a rare skin cancer which impacts
The regulator issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sarilumab, an investigational interleukin-6 receptor (IL-6R) antibody for the treatment of adult patients
Located in Mainz, Ganymed was established in 2001. It is engaged in the development of a new class of immunotherapeutic cancer drugs called ideal monoclonal antibodies (IMABs). The
Motus is a subsidiary of Rhythm Holding, which also owns Rhythm Pharmaceuticals. The acquisition will include Motus’ lead drug candidate relamorelin (RM-131), a ghrelin agonist being developed for
The trials in question are testing whether a drug called durvalumab, used alone or in combination with tremelimumab or other potential medicines, prolongs survival in patients with head
The phase III randomized, double-blind, parallel arm, multiple dose, active comparator study also met secondary endpoints. The study included 645 patients diagnosed with moderate to severe active RA
The companies did not disclose the value of the expanded collaboration, which features a new, three-year research partnership. Under the partnership, the companies will develop cognitive technologies to
The joint project will see Fimbrion and the Discovery Partnerships with Academia (DPAc) team at GSK focus on the preclinical development of a class of mannose-containing small molecule
The phase III SOLO-2 trial randomized 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least two prior lines of platinum-based chemotherapy. It showed
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.